1. Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma
- Author
-
Yuhki Sakuraoka, Yukihiro Iso, Keiichi Kubota, Takamune Yamaguchi, Shozo Mori, Takayuki Shimizu, Kyung Hwa Park, Takatsugu Matsumoto, Taku Aoki, and Takayuki Shiraki
- Subjects
Male ,Time Factors ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Disease ,Deoxycytidine ,Gastroenterology ,0302 clinical medicine ,Endocrinology ,Carcinoembryonic antigen ,Risk Factors ,Antineoplastic Combined Chemotherapy Protocols ,Aged, 80 and over ,biology ,Middle Aged ,Neoadjuvant Therapy ,Drug Combinations ,Treatment Outcome ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Pancreatectomy ,Female ,030211 gastroenterology & hepatology ,Carcinoma, Pancreatic Ductal ,medicine.drug ,Adult ,medicine.medical_specialty ,Pancreatic ductal adenocarcinoma ,Clinical Decision-Making ,Risk Assessment ,03 medical and health sciences ,Internal medicine ,Internal Medicine ,medicine ,Humans ,In patient ,Aged ,Retrospective Studies ,Tegafur ,Chemotherapy ,Hepatology ,business.industry ,Albumin ,Gemcitabine ,Pancreatic Neoplasms ,Oxonic Acid ,biology.protein ,Neoplasm Grading ,business - Abstract
Although neoadjuvant chemotherapy (NAC)-gemcitabine plus S-1 (GS) has been reported to have a survival benefit in patients with resectable pancreatic ductal adenocarcinoma (PDAC), optimal candidates for NAC-GS have not been clearly identified.A total of 81 patients with PDAC who underwent pancreatectomy after NAC-GS between 2013 and 2019 were divided into 2 groups based on Evans classification: grade I (10% tumor cell destruction, n = 19) and grades II and III (10% tumor cell destruction, n = 62). Univariate and multivariate analyses using clinical characteristics available before initiation of NAC were performed to predict Evans classification grade I (Evans I).The overall survival in patients with Evans I was significantly lower than that in patients with Evans II and III (P0.001). Multivariate analysis revealed a carcinoembryonic antigen level of3.6 ng/mL (P = 0.001) and C-reactive protein to albumin ratio of0.062 (P = 0.017) as independent predictors for Evans I disease. Seven of 11 patients who met both criteria had Evans I disease.Serum carcinoembryonic antigen and C-reactive protein to albumin ratio are associated with Evans I disease in patients with PDAC who receive NAC-GS. Patients who meet both predictors may not be optimal candidates for NAC-GS.
- Published
- 2021
- Full Text
- View/download PDF